To investigate whether effects on food intake are seen in obese subjects receiving exogenous administration of ghrelin. DESIGN: Randomised, double-blind, placebo-controlled study of intravenous ghrelin at doses 1 pmol/kg/min and 5 pmol/kg/ min. SUBJECTS: In all, 12 healthy lean subjects (mean body mass index (BMI) 20.570.17 kg/m 2 ) and 12 healthy overweight and obese subjects (mean BMI 31.971.02 kg/m 2 ). MEASUREMENTS: Food intake, appetite and palatability of food, ghrelin and other obesity-related hormones, growth hormone. RESULTS: Low-dose infusion of ghrelin increased ad libitum energy intake at a buffet meal in the obese group only (mean increase 36.679.4%, Po0.01.) High-dose ghrelin infusion increased energy intake in both groups (mean increase 20.1710.6% in the lean and 70.1715.5% in the obese, Po0.01 in both cases.) Ghrelin infusion increased palatability of food in the obese group. CONCLUSION: Ghrelin increases food intake in obese as well as lean subjects. Obese people are sensitive to the appetitestimulating effects of ghrelin and inhibition of circulating ghrelin may be a useful therapeutic target in the treatment of obesity.
Introduction
Ghrelin is a hormone synthesised in the stomach 1 and is the endogenous ligand for the growth hormone secretagogue receptor, 2, 3 which is expressed in hypothalamic nuclei including the arcuate nucleus and in brain stem nuclei. 4 Gastric expression and circulating levels of ghrelin are upregulated by fasting. [5] [6] [7] In rodents, ghrelin is a potent stimulus to feeding with maximum effects observed within an hour of peripheral administration. 8 The resultant plasma levels are comparable to those observed after a 24-h fast, 6 suggesting physiological relevance. Ghrelin levels fall after feeding. The mechanism has not been identified, but the fall in level appears to be influenced by gut nutrients rather than gastric distension as plasma ghrelin is suppressed by an oral glucose load but not altered by the same volume of water. 7 Chronic ghrelin administration induces adiposity 7 without attenuation of the effects on food intake. 6 In addition to its effects on appetite, ghrelin stimulates gastric emptying and increases gastric acid secretion in rodents. 9 Human data also support a role for ghrelin in appetite regulation. 10 As in rodents, ghrelin is principally secreted by the stomach and levels in postgastrectomy patients are around 35% of those of age-matched controls. 11 Plasma levels rise preprandially and fall within 1 h of eating, 12 suggesting that ghrelin may play a role in meal initiation as a hunger signal. 13 We have previously shown that exogenous infusion of ghrelin at a dose of 5.0 pmol/kg/min increased food intake at a buffet meal by 28% in normal weight human subjects, compared to a saline control day. 10 This was associated with a preprandial increase in appetite, while satiety after the meal was the same in both groups. Fasting levels of several of the circulating hormones that influence appetite regulation are different in obese people compared with their lean counterparts. For example, leptin is higher in obese people compared to lean 14 and PYY levels are lower in the obese. 15 Some studies have observed significantly lower basal levels of ghrelin in obese subjects compared to lean 16, 17 and ghrelin changes with alterations in body mass index (BMI), increasing after weight loss 18, 19 and falling with weight gain. 20 Sensitivity to appetite-regulating hormones may also differ between lean and obese groups. For example, while it was hoped that leptin could be used to promote weight loss, it proved ineffective in simple polygenic obesity, which is associated with leptin resistance.
14 In contrast, obese people appear to retain sensitivity to the appetite-inhibiting hormone PYY. 15 There is evidence that the effect of ghrelin on growth hormone secretion differs in lean and obese individuals with a smaller response in the obese. 21 It is not known whether obese individuals are responsive to the appetite-stimulating effects of ghrelin. To establish this would be a step towards greater understanding of the role of ghrelin in the aetiology of obesity. In addition, this may provide an insight into the potential utility of modification of ghrelin as an approach to the treatment of obesity.
Research design and methods

Subjects
Healthy lean and obese subjects were recruited by advertising in newspapers and on the Imperial College Campus in London. Ethical approval was obtained from the local ethics committee (project registration number 2000/5941) and the study was performed in accordance with the principles of the Declaration of Helsinki. In all, 24 subjects were recruited, 12 were lean and 12 were obese, with four males and eight females in each group. 23 They also completed food diaries to assess their usual dietary habits.
Protocol
The protocol design was based on previously published studies. 10, 24, 25 Each subject was studied on three occasions, and received three infusions -saline, low-dose ghrelin (1.0 pmol/kg/min) and high-dose ghrelin (5.0 pmol/kg/ min), in a double-blinded, randomised, crossover, Latin Square design. Each subject's study days were at least 48 h apart. Food intake was standardised and recorded for the 24 h prior to the study. All subjects fasted from 2100 h and drank only water from midnight on the evening prior to each study. Subjects refrained from alcohol and strenuous exercise for 24 h before and after each study day.
Subjects arrived at 0830 h on each study day. Cannulae were inserted into veins in both forearms, one for the infusion of ghrelin or saline and the other for the collection of blood samples. After venous cannulation, the subjects relaxed for 30 min before the start of the study protocol. Basal blood samples were taken at À30 and 0 min. All time cues were removed from the study room and subjects were encouraged to relax by reading and watching films. Infusions commenced at 0900 h (t ¼ 0) and continued for a total of 75 min. Further blood samples were taken at 15, 30, 45 and 75 min of infusion, plus 30 min after the end of the infusion. Blood samples were collected into plastic heparin-coated tubes (LIP Ltd, UK) containing 5000 kallikrein inhibitor units (0.2 ml aprotinin) (Bayer). Plasma was separated immediately by centrifugation at 41C and stored at À201C until assayed.
At 45 min, while the infusions continued, a buffet meal was served. All subjects had completed their meal by 75 min at which time the infusion was terminated. Visual analogue scales of 100 mm were used for rating hunger, nausea and fullness at baseline and prebreakfast, and for assessment of meal palatability after breakfast. 26 The subjects left the study room 30 min after cessation of the infusion and completed food diaries until 1300 h the following day to allow assessment of subsequent food intake. The food diaries were analysed by a dietitian unaware of study assignments and energy intake was calculated with the aid of Dietplan (Forestfield Software Ltd, West Sussex, UK).
Dose
Subjects received infusion of either ghrelin 5.0 pmol/kg/min in saline (high dose), or ghrelin 1.0 pmol/kg/min in saline (low dose), or saline alone, in random order. These doses were chosen on the basis of previous work carried out by the Department of Metabolic Medicine at Imperial College, London, in which an an intravenous infusion of ghrelin at a dose of 5.0 pmol/kg/min led to a significant increase in food intake in normal weight subjects at a test meal. 10 The lower dose of 1.0 pmol/kg/min was chosen in order to highlight any difference in sensitivity to ghrelin between the lean and obese groups. Infusion time was based on previous ghrelin infusion protocols.
Meal
Subjects were instructed to eat as much as they wanted from two standardised types of sandwiches, with fillings prearranged with subjects to ensure a choice suitable for them, and water to drink as required. Each subject received the Ghrelin in obese and lean subjects MR Druce et al same meal on each study visit, and thus macronutrient composition of the meal was constant. Food was offered in sufficient excess to satisfy all appetites and subjects were informed they could take away any uneaten food with them if desired. The meal was completed at a single sitting, all subjects having finished eating within 30 min while the infusion continued. The amounts of food and water were quantified preprandially and postprandially by a blinded investigator and the caloric intake calculated.
Materials
Human ghrelin was obtained from Bachem (Merseyside, UK.). The Limulus Amoebocyte Lysate Assay test for pyrogen was negative and the peptide was sterile on culture. Peptide was dissolved in 0.9% saline (Bayer, Haywards Heath, UK) containing Haemaccel (Beacon, Kent, UK) (10% by volume) to reduce adsorption to the syringe and tubing.
Assays Ghrelin-like immunoreactivity was measured with an established specific and sensitive radioimmunoassay. [27] [28] [29] The assay crossreacts fully (100%) with both octanoyl and des octanoyl ghrelin and did not crossreact with any known gastrointestinal or pancreatic peptide hormones. The antisera (SC-10368) was obtained from Santa Cruz biotechnology and used at a final dilution of 1:50 000. The 125 I ghrelin was prepared with Bolton & Hunter reagent (Amersham International, UK) and purified by RP-HPLC using a linear gradient from 10 to 40% acetonitrile, and 0.05% TFA over 90 min. The specific activity of ghrelin label was 48 Bq/fmol. The assay was performed in total volume of 0.7 ml of 0.06 M phosphate buffer pH 7.2 containing 0.3% BSA and was incubated for 3 days at 41C before separation of free and bound antibody by charcoal absorption. The assay detected changes of 25 pmol/l of plasma ghrelin with 95% confidence limit, with an intra-assay coefficient of variation 5.5%. All samples were measured in one assay to avoid interassay variation. Results were duplicated using a commercially available kit (Phoenix Pharmaceuticals, Belmont, CA, USA.) Insulin was measured using an established in-house radioimmunoassay. 30 Plasma leptin was measured with the Linco
Research kit (Missouri, USA). Growth hormone was quantified in the clinical reference laboratory by chemiluminescence immunoassay using the Nichols Advantage machine.
Statistical analysis
Subject characteristics are expressed as means 7s.d. Plasma ghrelin hormone levels are expressed as means7s.e.m. The integrated area under the curve was calculated using the trapezoid rule. Caloric intake is expressed as absolute kilocalories and as means7s.e.m., and as percentage change compared to baseline saline day. Comparison within groups having different treatments used paired t-tests (Sigmastat software.) Throughout, P-values less than 0.05 were considered significant.
Results
Subject characteristics
Subject characteristics are summarised in . The mean ages were 24.774.6 y in the lean group and 33.476.9 y in the obese group. Leptin levels were lower in the lean group (mean 6.2174.8 pmol/l) than in the obese group (18.6877.8 pmol/l). Leptin levels differed markedly between males and females. In the lean group, mean leptin was 1.8570.5 pmol/l for males and 8.3974.4 pmol/l for females. In the obese group, mean leptin was 10.777.0 pmol/l for males and 22.6674.9 pmol/l for females. Cholesterol was higher in the obese group (5.5971.1 mmol/l) than in the lean group (4.4670.9 mmol/l).
Plasma ghrelin
Mean basal ghrelin in the lean group was 459.6745.2 pmol/l and in the obese group was 440.8749.1 pmol/l. There was no statistically significant difference between the lean and obese groups or between levels in males and females.
Ghrelin levels achieved are shown in Figure 1 . Peak premeal ghrelin levels achieved (at 45 min infusion) were comparable in lean and obese groups for the low dose of ghrelin. The peak in the lean group was 725.7741.3 pmol/l and in the obese group 745.5740.4 pmol/l. These levels correspond to 1.6-and 1.7-fold increases compared to the ghrelin concentration in these groups at the same point on the saline infusion day. The peak ghrelin level in the lean group following high-dose ghrelin infusion was lower than in the obese group with a value of 1598.27143.5 pmol/l as compared to 2118.97139.9 pmol/l. With the high-dose infusion, the peak ghrelin level reached was 3.6-fold greater Ghrelin in obese and lean subjects MR Druce et al than at the same point during saline infusion in the lean group, and five-fold greater in the obese group. The areas under the curve over the 45 min infusion showed no statistically significant difference for the low dose, with values of 7.870.8 and 9.170.9 nmol/l/min for the lean and obese groups, respectively. However, following the high-dose infusion, the area under the curve was lower for the lean than obese group with values of 31.872.2 and 42.872.6 nmol/l/min, respectively (P ¼ 0.02).
Effects of Ghrelin infusion on food intake
On the saline day, mean food intake for the obese group was 754.07136.9 kcal (3156.87573.2 kJ.) Mean food intake for the lean group was 750.67106.5 kcal (3142.67445.9 kJ.) In obese subjects, low-dose ghrelin infusion significantly increased the energy intake on the ghrelin day compared to the saline day: mean increase 165.8745.9 kcal (694.27192.2 kJ), P ¼ 0.004. Low-dose exogenous ghrelin infusion tended to increase energy intake in the lean group compared to intake on the saline day; however, this was not statistically significant: mean increase 128.7767.1 kcal (538.87280.9 kJ), P ¼ 0.08. High-dose exogenous ghrelin infusion increased energy intake in both the lean and obese groups. In the obese group, the mean increase was 380.57100.0 kcal (1593.17418.7 kJ), where P ¼ 0.003 when compared to saline. In the lean group, the mean increase was 118.1746.8 kcal (4944.67195.9 kJ), where P ¼ 0.004 when compared to saline.
In percentage terms, the increases in energy intake during the buffet meal following ghrelin infusion, as shown in Figure 2 , were as follows. In the obese group, the mean increases were 36.679.4% on the low-dose day and 70.17 15.5% on the high-dose day. In the lean group, the mean increases were 20.2710.8% on the low-dose infusion day and 20.1710.6% on the high-dose day.
There was no effect on food intake in any group during the 24 h following the infusion, that is, there was no sustained increase in food intake, nor was there a rebound reduction in calories consumed following the cessation of infusion (data not shown.)
Effects of ghrelin infusion on appetite and food palatability Infusion of ghrelin at low dose did not result in any significant changes in scores of appetite or hunger, in either lean or obese subjects, as measured by visual analogue scales. Infusion of high-dose ghrelin resulted in an increase in score for the question 'how hungry do you feel' in both lean and obese subjects (P ¼ 0.004 and 0.03, respectively) and a fall in score for the question 'how full do you feel' in both lean and obese subjects (P ¼ 0.02 and 0.03, respectively) at 30 min after injection. No subjects developed nausea during infusion. Ghrelin in obese and lean subjects MR Druce et al
Visual analogue scores for the palatability of the food offered at the buffet breakfast ( Figure 3) showed no significant differences between infusion days in the lean group. In the obese group, palatability was increased by a mean of 17.577.4% compared to saline on the low-dose infusion day and 21.378.7% compared to saline on the high-dose infusion day (P ¼ 0.04 in both cases) (Figure 3) .
Effects of ghrelin infusion on growth hormone secretion Peak growth hormone was achieved at 45 min after the start of the infusion of ghrelin. After low dose, the mean growth hormone increment from baseline to peak (compared to that on the saline day) was 40.378.8 mIU/l in the lean group and 20.874.7 mIU/l in the obese group (P ¼ 0.06). At high dose, the increment in the lean group was 201.2743.7 mIU/l in the lean group and 69.3717.8 mIU/l in the obese group (P ¼ 0.01.) This is shown in Figure 4 .
Discussion
Ghrelin is a circulating hormone shown to promote feeding and adiposity following administration in rodents. 6, 7 In addition, ghrelin stimulates appetite and food intake in humans. 10 In this current investigation, we aimed to investigate whether ghrelin acts to increase appetite and food intake in obese individuals. This finding may provide insight into the aetiology of obesity and would also help to elucidate whether ghrelin would be a suitable candidate as a therapeutic target in the treatment of obesity. Other groups have observed a difference in fasting plasma ghrelin concentrations between lean and obese humans, with higher ghrelin levels in lean individuals. 16, 17 These observations have led to the hypothesis that ghrelin acts as a counterregulatory hormone, rising in lean people to stimulate appetite and weight gain and falling in obesity to limit energy intake. The different basal levels may be reflected in different responsiveness to the appetite-stimulating effects of ghrelin. Furthermore, there is some evidence to suggest that the normal postprandial fall in ghrelin is attenuated in the obese. 31 This could result in decreased postprandial satiety, further increasing food intake. The mechanism underlying the decreased ghrelin associated with obesity remains unclear.
In this study, we found no significant difference in basal ghrelin levels between the lean and obese individuals. This finding was somewhat surprising. The ghrelin measurements were repeated with a widely available commercial assay (Phoenix Pharmaceuticals, Belmont, CA, USA), which confirmed the initial findings with our assay. However, the lean and obese groups clearly differed with respect to BMI, leptin, insulin and cholesterol levels as expected. The observation that circulating ghrelin is inversely proportional to BMI comes from investigations of subjects including more individuals at the extremes of the BMI range. 16 Other studies have focused on such extremes, for example, many subjects with BMI o18.5 due to anorexia nervosa in one 17 and severely obese subjects with BMI 33-65 kg/m 2 in another. 32 The relationship between BMI and ghrelin is nonlinear. 33 A significant difference may be more difficult to demonstrate in our cohort of volunteers, who were purposely chosen with a narrower BMI range (19.6-39 kg/m 2 ) in order to more closely reflect the spectrum of body weight in healthy normal weight and overweight individuals. Indeed, other published studies have also used cohorts of healthy lean and obese subjects with no difference in basal ghrelin. 34 Although mean fasting ghrelin levels do not differ between the two groups, other classical markers of obesity are altered as expected in our cohort. Thus basal leptin and insulin levels and fasting cholesterol are all higher in the obese group.
Low-dose ghrelin infusion led to similar plasma levels in the lean and obese groups. Overall the circulating ghrelin Ghrelin in obese and lean subjects MR Druce et al level reached at the time of presentation of the buffet meal was similar (1.6 and 1.7 times the level seen at the same point on the saline infusion day) with a comparable cumulative elevation of plasma ghrelin in each case (as estimated by area under the curve.) In comparison the high dose resulted in a significant difference in plasma concentration at the time of presentation of the meal and also in total area under the curve between the lean and obese groups. Therefore, we have applied statistical calculations to both doses administered (reflecting the experimental design), but for the purposes of this discussion, we will focus mainly on the food intake results obtained following lowdose infusion. This will enable comparison of the effects of equivalent plasma levels of ghrelin achieved in the two groups.
The low-dose infusion of ghrelin, which led to a peak ghrelin level of 1.6-1.7 times that observed on the saline control day, resulted in a mean increase of 20.2% in food intake in the lean group and 36.6% in the obese group. This change was statistically significant for the obese group (Po0.05), and thus it is clear that obese people retain sensitivity to exogenous infusion of ghrelin. It may be noted that after high-dose infusion, there was a mean increase in food intake of 20.1% in the lean group and 70.1% in the obese group. In both groups, the high dose led to a statistically significant increase in food intake compared to the saline control day (Po0.05 and o0.01, respectively). However, the differences in plasma levels achieved after high dose in the lean and obese groups preclude further analysis.
It is helpful to examine the food intake response following intravenous ghrelin in published work, although direct comparison would not be valid due to differences in infusion duration and experimental paradigm. Wren et al 10 reported
that an intravenous infusion of ghrelin of 5 pmol/kg/min resulted in a 28% increase in food intake. Visual analogue scores of hunger and fullness did not show statistically significant differences compared to saline in the lean group following administration of ghrelin. However, in the obese group, low-dose ghrelin increased the palatability of food at the buffet meal by a mean of 17.5% and high dose by 21.3% (Po0.05 in both cases). It could be that enhancement of food palatability following ghrelin administration resulted in the increased food intake.
These findings indicate that ghrelin sensitivity is retained in obese individuals and therefore ghrelin receptor antagonists may prove to be useful appetite-reducing agents. Further studies of the effects of ghrelin antagonists in both normal weight and obese humans are now warranted to test this further. There is some evidence of reduced food intake in rodents following administration of ghrelin antagonists, 35 but the effects of these agents in human subjects have not been investigated.
A further interesting observation in our study is the effect of ghrelin administration on the growth hormone response. Obesity is characterised by several endocrine abnormalities including reduction of both spontaneous and stimulated growth hormone secretion. It has been postulated that the effect could be due to the lower endogenous levels of growth hormone secretagogues such as ghrelin. However, in our study, the growth hormone response in the obese group is blunted at both doses of ghrelin administered despite endogenous fasting ghrelin concentrations, which did not differ significantly from those of the lean group. This contrasts with the maintained effect of ghrelin on food intake in the obese group. At the high dose in particular, the obese group had a significantly higher mean ghrelin level (1.3 times that of the lean group) yet the growth hormone response was almost three times as great in the lean group. This corroborates the impairment in growth hormone response to ghrelin in the obese observed by other groups. 21 Interestingly, the growth hormone response to ghrelin is also blunted in patients with anorexia nervosa who have high ghrelin levels. 36 In our cohort, the effect may also be enhanced by the greater age in the obese group, as age also results in a blunting of the growth hormone response to ghrelin. 37 In summary, we have observed that the feeding response to ghrelin is maintained in obesity. In contrast, the growth hormone response to ghrelin is attenuated. Ghrelin is a stimulus to food intake and its effects may contribute to the aetiology of obesity. Furthermore this highlights ghrelin as a potential therapeutic target in strategies to treat obesity. Further work with ghrelin-blocking agents is indicated to elucidate this further.
